Published in Biochem Pharmacol on March 17, 2012
Crystal structure of 4-oxo-4H-chromene-3-carb-oxy-lic acid. Acta Crystallogr E Crystallogr Commun (2015) 0.75
A comparison of the structures of some 2- and 3-substituted chromone derivatives: a structural study on the importance of the secondary carboxamide backbone for the inhibitory activity of MAO-B. Acta Crystallogr E Crystallogr Commun (2015) 0.75
Polymorphism in the structure of N-(5-methyl-thia-zol-2-yl)-4-oxo-4H-chromene-3-carboxamide. Acta Crystallogr E Crystallogr Commun (2017) 0.75
FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell (2009) 4.11
Analysis of receptor oligomerization by FRAP microscopy. Nat Methods (2009) 2.06
The mitochondrial calcium uniporter is a multimer that can include a dominant-negative pore-forming subunit. EMBO J (2013) 1.86
USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol (2011) 1.61
Role of the beta1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo. Anesthesiology (2006) 1.55
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol (2006) 1.48
Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem (2007) 1.37
Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem (2008) 1.32
Anticancer activity of phenolic acids of natural or synthetic origin: a structure-activity study. J Med Chem (2003) 1.31
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol (2002) 1.27
Drug-drug interaction through molecular structure similarity analysis. J Am Med Inform Assoc (2012) 1.25
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem (2002) 1.22
Protein kinase CK2 inhibitors: a patent review. Expert Opin Ther Pat (2012) 1.21
Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry (2004) 1.16
Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther (2002) 1.15
Chromone: a valid scaffold in medicinal chemistry. Chem Rev (2014) 1.15
Combining QSAR classification models for predictive modeling of human monoamine oxidase inhibitors. Eur J Med Chem (2012) 1.14
Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship. Chem Res Toxicol (2006) 1.13
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem (2011) 1.12
MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharmacol (2011) 1.09
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother (2011) 1.09
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett (2009) 1.08
8-Substituted 3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation, and docking studies. ChemMedChem (2012) 1.08
New halogenated phenylcoumarins as tyrosinase inhibitors. Bioorg Med Chem Lett (2011) 1.07
Synthesis, conformational analysis and antiviral and antitumoral activity of new 1,2-disubstituted carbocyclic nucleosides. Eur J Med Chem (2002) 1.06
Proteomics, networks and connectivity indices. Proteomics (2008) 1.05
Mitochondrial dysfunction and caspase activation in rat cortical neurons treated with cocaine or amphetamine. Brain Res (2006) 1.05
Methamphetamine-induced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain. Ann N Y Acad Sci (2008) 1.04
Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur J Neurosci (2010) 1.03
Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J (2009) 1.02
Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol (2004) 1.00
Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res (2011) 0.99
Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem (2003) 0.99
Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal. Br J Pharmacol (2005) 0.99
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. J Med Chem (2002) 0.99
Hemolytic effects of water-soluble fullerene derivatives. J Med Chem (2004) 0.98
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. J Med Chem (2002) 0.98
Lipophilic phenolic antioxidants: correlation between antioxidant profile, partition coefficients and redox properties. Bioorg Med Chem (2010) 0.98
Structure-property studies on the antioxidant activity of flavonoids present in diet. Free Radic Biol Med (2005) 0.97
Swimming into peptidomimetic chemical space using pepMMsMIMIC. Nucleic Acids Res (2011) 0.97
Hydroxycinnamic acid antioxidants: an electrochemical overview. Biomed Res Int (2013) 0.97
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile. Purinergic Signal (2006) 0.96
MMsINC: a large-scale chemoinformatics database. Nucleic Acids Res (2008) 0.96
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem (2008) 0.95
Enhancing adverse drug event detection in electronic health records using molecular structure similarity: application to pancreatitis. PLoS One (2012) 0.95
Detection of drug-drug interactions by modeling interaction profile fingerprints. PLoS One (2013) 0.95
Evidence for the Recognition of Non-Nucleotide Antagonists Within the Transmembrane Domains of the Human P2Y(1) Receptor. Drug Dev Res (2002) 0.95
New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett (2010) 0.95
New water soluble pyrroloquinoline derivatives as new potential anticancer agents. Bioorg Med Chem (2005) 0.94
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B. Bioorg Med Chem Lett (2010) 0.94
GTP-dependent packing of a three-helix bundle is required for atlastin-mediated fusion. Proc Natl Acad Sci U S A (2011) 0.94
Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem (2006) 0.94
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. J Med Chem (2014) 0.94
Medicinal chemistry and bioinformatics--current trends in drugs discovery with networks topological indices. Curr Top Med Chem (2007) 0.94
Natural/random protein classification models based on star network topological indices. J Theor Biol (2008) 0.93
4-Oxo-N-phenyl-4H-chromene-2-carboxamide and of a new polymorph of 7-methoxy-4-oxo-N-p-tolyl-4H-chromene-2-carboxamide and its hemihydrate. Acta Crystallogr C (2013) 0.92
Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. J Med Chem (2012) 0.92
Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action. J Med Chem (2006) 0.92
Street heroin induces mitochondrial dysfunction and apoptosis in rat cortical neurons. J Neurochem (2007) 0.92
Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol (2002) 0.92
Lipophilic caffeic and ferulic acid derivatives presenting cytotoxicity against human breast cancer cells. Chem Res Toxicol (2011) 0.92
Antioxidant profile of dihydroxy- and trihydroxyphenolic acids--a structure-activity relationship study. Free Radic Res (2006) 0.92
Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. Thyroid (2014) 0.92
Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20. Mol Pharmacol (2005) 0.92
Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry. Biochem Pharmacol (2012) 0.91
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem (2006) 0.91
Toward efficient Zn(II)-based artificial nucleases. J Am Chem Soc (2004) 0.91
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem (2007) 0.89
Alkyl esters of hydroxycinnamic acids with improved antioxidant activity and lipophilicity protect PC12 cells against oxidative stress. Biochimie (2011) 0.89
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. J Med Chem (2009) 0.89
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol (2005) 0.89
SAR and QSAR study on 2-aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease. Bioorg Med Chem (2008) 0.89
State of the art and development of a drug-drug interaction large scale predictor based on 3D pharmacophoric similarity. Curr Drug Metab (2014) 0.88
Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin Ther Pat (2009) 0.88
9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.88
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors. J Med Chem (2011) 0.88
5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. Bioorg Med Chem (2007) 0.88
Alignment-free prediction of polygalacturonases with pseudofolding topological indices: experimental isolation from Coffea arabica and prediction of a new sequence. J Proteome Res (2009) 0.88
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. J Med Chem (2009) 0.88
Receptor crosstalk: haloperidol treatment enhances A(2A) adenosine receptor functioning in a transfected cell model. Purinergic Signal (2010) 0.87
Antioxidant therapy: still in search of the 'magic bullet'. Mitochondrion (2012) 0.87
Interactions of flavones and other phytochemicals with adenosine receptors. Adv Exp Med Biol (2002) 0.87
Structural characterization of some N-phenyl-4-oxo-4H-2-chromone carboxamides. Acta Crystallogr B Struct Sci Cryst Eng Mater (2013) 0.87